Cargando…

Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer

Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 may play a role in the pathogenesis of cancer disease. We investigated their levels and utility in comparison to cancer antigen (CA) 15-3 in patients with breast cancer (BC) and in rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Ławicki, Sławomir, Zajkowska, Monika, Głażewska, Edyta Katarzyna, Będkowska, Grażyna Ewa, Szmitkowski, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771393/
https://www.ncbi.nlm.nih.gov/pubmed/26966379
http://dx.doi.org/10.2147/OTT.S99959
_version_ 1782418388700626944
author Ławicki, Sławomir
Zajkowska, Monika
Głażewska, Edyta Katarzyna
Będkowska, Grażyna Ewa
Szmitkowski, Maciej
author_facet Ławicki, Sławomir
Zajkowska, Monika
Głażewska, Edyta Katarzyna
Będkowska, Grażyna Ewa
Szmitkowski, Maciej
author_sort Ławicki, Sławomir
collection PubMed
description Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 may play a role in the pathogenesis of cancer disease. We investigated their levels and utility in comparison to cancer antigen (CA) 15-3 in patients with breast cancer (BC) and in relation to the control groups. The study included 100 women with BC, 50 patients with benign breast tumor, and 50 healthy women. The plasma levels of the tested parameters were determined using enzyme-linked immunosorbent assay, while CA 15-3 with chemiluminescent microparticle immunoassay. The results demonstrated significant differences in the concentration of the tested parameters and CA 15-3 between groups of patients with BC and healthy patients or patients with benign breast tumor. The plasma levels of VEGF and tissue inhibitor of metalloproteinase-1 were significantly higher in advanced tumor stages. The tested parameters were comparable to CA 15-3 values of the diagnostic sensitivity, specificity, the predictive values of positive and negative test results, and the area under the receiver-operating characteristic curve. The combined use of the tested parameters with CA 15-3 resulted in the increase in sensitivity, negative predictive value, and area under the receiver-operating characteristic curve, especially in the combination of VEGF with tumor marker (84%, 73%, 0.888, respectively). These findings suggest the usefulness of the tested parameters in the diagnosis of BC. VEGF, especially in combination with CA 15-3, showed the highest usefulness in the diagnosis of early BC.
format Online
Article
Text
id pubmed-4771393
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-47713932016-03-10 Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer Ławicki, Sławomir Zajkowska, Monika Głażewska, Edyta Katarzyna Będkowska, Grażyna Ewa Szmitkowski, Maciej Onco Targets Ther Original Research Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 may play a role in the pathogenesis of cancer disease. We investigated their levels and utility in comparison to cancer antigen (CA) 15-3 in patients with breast cancer (BC) and in relation to the control groups. The study included 100 women with BC, 50 patients with benign breast tumor, and 50 healthy women. The plasma levels of the tested parameters were determined using enzyme-linked immunosorbent assay, while CA 15-3 with chemiluminescent microparticle immunoassay. The results demonstrated significant differences in the concentration of the tested parameters and CA 15-3 between groups of patients with BC and healthy patients or patients with benign breast tumor. The plasma levels of VEGF and tissue inhibitor of metalloproteinase-1 were significantly higher in advanced tumor stages. The tested parameters were comparable to CA 15-3 values of the diagnostic sensitivity, specificity, the predictive values of positive and negative test results, and the area under the receiver-operating characteristic curve. The combined use of the tested parameters with CA 15-3 resulted in the increase in sensitivity, negative predictive value, and area under the receiver-operating characteristic curve, especially in the combination of VEGF with tumor marker (84%, 73%, 0.888, respectively). These findings suggest the usefulness of the tested parameters in the diagnosis of BC. VEGF, especially in combination with CA 15-3, showed the highest usefulness in the diagnosis of early BC. Dove Medical Press 2016-02-24 /pmc/articles/PMC4771393/ /pubmed/26966379 http://dx.doi.org/10.2147/OTT.S99959 Text en © 2016 Ławicki et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Ławicki, Sławomir
Zajkowska, Monika
Głażewska, Edyta Katarzyna
Będkowska, Grażyna Ewa
Szmitkowski, Maciej
Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer
title Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer
title_full Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer
title_fullStr Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer
title_full_unstemmed Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer
title_short Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer
title_sort plasma levels and diagnostic utility of vegf, mmp-9, and timp-1 in the diagnosis of patients with breast cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771393/
https://www.ncbi.nlm.nih.gov/pubmed/26966379
http://dx.doi.org/10.2147/OTT.S99959
work_keys_str_mv AT ławickisławomir plasmalevelsanddiagnosticutilityofvegfmmp9andtimp1inthediagnosisofpatientswithbreastcancer
AT zajkowskamonika plasmalevelsanddiagnosticutilityofvegfmmp9andtimp1inthediagnosisofpatientswithbreastcancer
AT głazewskaedytakatarzyna plasmalevelsanddiagnosticutilityofvegfmmp9andtimp1inthediagnosisofpatientswithbreastcancer
AT bedkowskagrazynaewa plasmalevelsanddiagnosticutilityofvegfmmp9andtimp1inthediagnosisofpatientswithbreastcancer
AT szmitkowskimaciej plasmalevelsanddiagnosticutilityofvegfmmp9andtimp1inthediagnosisofpatientswithbreastcancer